Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study
暂无分享,去创建一个
P. Lescuyer | M. Imboden | A. Flahault | A. Azman | N. Rodondi | M. Puhan | A. Camerini | M. Bochud | A. Chiolero | I. Guessous | L. Corna | S. Stringhini | N. Noël | T. Radtke | A. Butty | J. Pasquier | S. Kriemler | A. Frei | E. Albanese | D. Keidel | R. Morese | K. Zens | Sara Levati | L. Crivelli | P. Bodenmann | V. von Wyl | Maddalena Fiordelli | M. Tonolla | M. Zaballa | A. Schmid | N. Pullen | D. Menges | H. Aschmann | M. Kaufmann | T. Ballouz | J. Villers | A. Wisniak | G. Piumatti | H. Baysson | A. Ulytė | S. Sabatini | O. Duperrex | D. Paris | V. D'Acremont | P. Rodondi | A. Loizeau | A. M. Annoni | N. Ortega | N. Troillet | Julia Vincentini | Géraldine Poulain | C. Kahlert | S. Cullati | D. Anker | C. Robert | C. Martinez | M. Fadda | A. Anagnostopoulos | E. Harju | A. Domenghino | É. Masserey | P. Kohler | P. Chocano-Bedoya | A. Epure | J. Magnin | E. Lorthe | R. Dumont | V. Richard | N. Schwab | A. Cusini | Marco Geigges | S. Pfister | A. Jeong | Rylana Wenger | Aude Richard | M. Rasi | N. Probst-Hensch | Prune Collombet | C. Wagner | M. Schüpbach | S. Gonseth Nusslé | S. Tancredi | Simone Kessler | S. Estoppey | Richard Dubos | A. Felappi | Erin A. West | L. Kaiser | C. Semaani | J. Fehr | J. Dupraz | Vincent Faivre | J. Thabard | R. Amati | C. Zuppinger | Sophie Vassaux | A. Steiner-Dubuis | Kleona Bezani | Gisela Michel | Alexandre Speierer | Giovanni Franscella | A. Blattmann | Luc Fornerod | I. Frank | Thomas Vermes | Antonio Amendola | Agathe Deschamps | Malik Egger | Natalie Engler | Marion Frangville | Irène Frank | Emilie Jendly | Caroline Pugin | V. Schlüter | Valentine Schneider | P. D’ippolito | Christine Krähenbühl | Clément Graindorge | Antoine Bal | Patrick Bleich | Natalie Francioli | Séverine Harnal | Khadija Samir | Stéphanie Testini | Nacira El Merjani | Francesco Pennacchio | Peter Buttaroni | Chantal Luedi | Melissa Witzig | Nicolai Mösli | Julien Lamour | J. Zozaya | L. Kaufmann | Moa Lina Haller | Chantal Lüdi | Antonio Alexia Daniela Anna Maria Hélène Andrew Antoine Ta Amendola Anagnostopoulos Anker Annoni Asc | Diana Sofia Da Costa Santos | Emna El-May | Lukas Erksam | Cristina Fragoso Corti | E. West | Jennifer Villers | Patricia Chocano-Bedoya | Laurie M. Corna
[1] F. Jalali,et al. Inequality in the distribution of Covid-19 vaccine: a systematic review , 2022, International Journal for Equity in Health.
[2] N. Rodondi,et al. Is living in a household with children associated with SARS-CoV-2 seropositivity in adults? Results from the Swiss national seroprevalence study Corona Immunitas , 2022, BMC Medicine.
[3] V. von Wyl,et al. Differences in COVID-19 vaccination uptake in the first 12 months of vaccine availability in Switzerland - a prospective cohort study. , 2022, Swiss medical weekly.
[4] C. Alpuche-Aranda,et al. Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico , 2022, Nature communications.
[5] C. Kaplan,et al. Relationship between mask wearing, testing, and vaccine willingness among Los Angeles County adults during the peak of the COVID-19 pandemic , 2021, Translational behavioral medicine.
[6] A. Rezapour,et al. Effectiveness of non-pharmaceutical public health interventions against COVID-19: A systematic review and meta-analysis , 2021, PloS one.
[7] Z. Ademi,et al. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis , 2021, BMJ.
[8] D. Mouly,et al. Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study , 2021, BMJ Open.
[9] J. Singleton,et al. Racial and Ethnic Disparities in COVID-19 Vaccination Coverage: The Contribution of Socioeconomic and Demographic Factors , 2021, American Journal of Preventive Medicine.
[10] A. Azman,et al. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[11] Neeti Zaman Bintee,et al. The Impact of Community Masking on COVID-19: A Cluster-Randomized Trial in Bangladesh , 2021 .
[12] A. Chiolero,et al. Elimination of covid-19: beware of surveillance bias , 2021, BMJ.
[13] P. Hotez,et al. Update on SARS-CoV-2 seroprevalence: regional and worldwide , 2021, Clinical Microbiology and Infection.
[14] A. Galvani,et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis , 2021, Proceedings of the National Academy of Sciences.
[15] G. Severi,et al. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study , 2021, International journal of epidemiology.
[16] John P. Moore,et al. Predictors of Nonseroconversion after SARS-CoV-2 Infection , 2021, Emerging infectious diseases.
[17] S. Cauchemez,et al. Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control study , 2021, The Lancet Regional Health - Europe.
[18] Belayneh Mengist,et al. Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis , 2021, PloS one.
[19] M. Nussenzweig,et al. Evolution of antibody immunity to SARS-CoV-2 , 2021, Nature.
[20] A. Flahault,et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study , 2020, medRxiv.
[21] M. van Boven,et al. Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave , 2020, Journal of Epidemiology & Community Health.
[22] D. Clifton,et al. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis , 2020, medRxiv.
[23] P. Galanis,et al. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis , 2020, Journal of Hospital Infection.
[24] G. Pantaleo,et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies , 2020, Journal of Virology.
[25] M. Imboden,et al. Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland , 2020, International Journal of Public Health.
[26] P. Glasziou,et al. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review , 2020, PloS one.
[27] A. Flahault,et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.
[28] Joshua M Sharfstein,et al. Diagnostic Testing for the Novel Coronavirus. , 2020, JAMA.
[29] P. Harris,et al. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.
[30] F. Reinach,et al. Population-based age-stratified seroepidemiological investigation , 2020 .
[31] Doojin Song. Università della Svizzera Italiana , 2004 .
[32] M. Reavey,et al. University of Lausanne , 1937, Nature.